NASDAQ:ALNY 20 December 2025

Alnylam stock dips as Amvuttra sales miss some forecasts; 2026 outlook in focus

Shares of Alnylam Pharmaceuticals slipped 0.1% to $370.39 in Tuesday afternoon trading, as investors weighed the company's updated sales forecast alongside its new five-year strategy.

13 January 2026

Earnings Reports·NASDAQ:ALNY·Stock Market

Alnylam stock sinks nearly 7% after Amvuttra revenue miss; what to watch next for ALNY

Alnylam Pharmaceuticals’ shares fell sharply on Monday after the drugmaker’s preliminary fourth-quarter sales for its flagship heart drug Amvuttra came in below Wall Street expectations.

13 January 2026

Earnings Reports·NASDAQ:ALNY·Pharmaceuticals·Stock Market

Alnylam stock slides after “Alnylam 2030” plan, Amvuttra Q4 sales come up short

Alnylam Pharmaceuticals shares dropped in late Monday trading after the RNA interference drugmaker unveiled a new five-year plan and provided early 2026 sales guidance, along with preliminary figures for 2025. The stock slipped roughly 6.7% to $370.91.

12 January 2026

Earnings Reports·NASDAQ:ALNY·Pharmaceuticals·Stock Market

Alnylam Pharmaceuticals (ALNY) Stock After Hours: Nasdaq-100 debut, fresh catalysts, and what to watch before Tuesday’s open (Dec. 23)

Dec. 22, 2025 — After the closing bell, Alnylam Pharmaceuticals, Inc. is finishing the day in the spotlight for a reason that has nothing to do with a clinical readout—at least not directly. Monday marked the company’s first trading day as a Nasdaq-100 constituent, a mechanical event that can reshape near-term flows even when the underlying business story is unchanged.

23 December 2025

Nasdaq-100·NASDAQ:ALNY·Pharmaceuticals·Stock Market

Alnylam Pharmaceuticals (ALNY) Stock on Dec. 22, 2025: Nasdaq-100 Debut, AMVUTTRA Momentum, Analyst Price Targets and the 2026 Outlook

Dec. 22, 2025 — Alnylam Pharmaceuticals, Inc. is stepping into a new tier of market visibility today as its Nasdaq-100 Index membership takes effect ahead of the opening bell—an index catalyst that can influence near-term trading and broaden long-term institutional ownership. Nasdaq+1

22 December 2025

Nasdaq-100·NASDAQ:ALNY·Pharmaceuticals·Stock Market

Alnylam Pharmaceuticals (ALNY) Stock: Nasdaq-100 Entry, Amvuttra Momentum, Analyst Targets and Key Risks to Know Before the Dec. 22, 2025 Market Open

Ahead of the U.S. stock market open on Monday, December 22, 2025, Alnylam Pharmaceuticals, Inc. is stepping into a new spotlight—not just for biotech fundamentals, but also for a major index catalyst that can reshape short-term trading dynamics.

22 December 2025

Nasdaq-100·NASDAQ:ALNY·Pharmaceutical Industry·Stock Market

Alnylam Pharmaceuticals (ALNY) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025

As of Saturday, December 20, 2025, investors are digesting a busy stretch of developments around Alnylam Pharmaceuticals, Inc.—from Nasdaq-100 index inclusion to fresh reimbursement tailwinds in the U.K. and continued focus on Amvuttra as the company’s main growth engine. Nasdaq+1

20 December 2025

Financial Forecasts·NASDAQ:ALNY

Alnylam Pharmaceuticals (ALNY) Stock After Hours: What Happened After the Dec. 19, 2025 Close — and What to Watch Before the Next Market Open

Alnylam Pharmaceuticals, Inc. finished Friday, December 19, 2025, with shares around $400 and little change in after-hours trading — but the setup into the next U.S. session looks more eventful than the calm “after the bell” tape suggests. ALNY ended the day near $400.23, after trading roughly between the mid-$395s and low-$408s on heavy volume. Investing.com

20 December 2025

NASDAQ:ALNY·Stock Market

NASDAQ:ALNY 20 December 2025 - 13 January 2026